Cargando…

Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia

BACKGROUND: Currently, there is lack of marker to accurately assess the prognosis of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC). This study aims to establish a hypoxia-related risk scoring model that can effectively predict the prognosis and chemotherapy outcomes of PDAC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Min, Feng, Liaoliao, Zong, Rongrong, Sun, Huiru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464224/
https://www.ncbi.nlm.nih.gov/pubmed/37605192
http://dx.doi.org/10.1186/s12957-023-03142-2
_version_ 1785098419811909632
author Ren, Min
Feng, Liaoliao
Zong, Rongrong
Sun, Huiru
author_facet Ren, Min
Feng, Liaoliao
Zong, Rongrong
Sun, Huiru
author_sort Ren, Min
collection PubMed
description BACKGROUND: Currently, there is lack of marker to accurately assess the prognosis of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC). This study aims to establish a hypoxia-related risk scoring model that can effectively predict the prognosis and chemotherapy outcomes of PDAC patients. METHODS: Using unsupervised consensus clustering algorithms, we comprehensively analyzed The Cancer Genome Atlas (TCGA) data to identify two distinct hypoxia clusters and used the weighted gene co-expression network analysis (WGCNA) to examine gene sets significantly associated with these hypoxia clusters. Then univariate Cox regression, the least absolute shrinkage and selection operator (LASSO) Cox regression and multivariate Cox regression were used to construct a signature and its efficacy was evaluated using the International Cancer Genome Consortium (ICGC) PDAC cohort. Further, the correlation between the risk scores obtained from the signature and carious clinical, pathological, immunophenotype, and immunoinfiltration factors as well as the differences in immunotherapy potential and response to common chemotherapy drugs between high-risk and low-risk groups were evaluated. RESULTS: From a total of 8 significantly related modules and 4423 genes, 5 hypoxia-related signature genes were identified to construct a risk model. Further analysis revealed that the overall survival rate (OS) of patients in the low-risk group was significantly higher than the high-risk group. Univariate and multivariate Cox regression analysis showed that the risk scoring signature was an independent factor for prognosis prediction. Analysis of immunocyte infiltration and immunophenotype showed that the immune score and the anticancer immune response in the high-risk were significantly lower than that in the low-risk group. CONCLUSION: The constructed hypoxia-associated prognostic signature demonstrated could be used as a potential risk classifier for PDAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03142-2.
format Online
Article
Text
id pubmed-10464224
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104642242023-08-30 Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia Ren, Min Feng, Liaoliao Zong, Rongrong Sun, Huiru World J Surg Oncol Research BACKGROUND: Currently, there is lack of marker to accurately assess the prognosis of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC). This study aims to establish a hypoxia-related risk scoring model that can effectively predict the prognosis and chemotherapy outcomes of PDAC patients. METHODS: Using unsupervised consensus clustering algorithms, we comprehensively analyzed The Cancer Genome Atlas (TCGA) data to identify two distinct hypoxia clusters and used the weighted gene co-expression network analysis (WGCNA) to examine gene sets significantly associated with these hypoxia clusters. Then univariate Cox regression, the least absolute shrinkage and selection operator (LASSO) Cox regression and multivariate Cox regression were used to construct a signature and its efficacy was evaluated using the International Cancer Genome Consortium (ICGC) PDAC cohort. Further, the correlation between the risk scores obtained from the signature and carious clinical, pathological, immunophenotype, and immunoinfiltration factors as well as the differences in immunotherapy potential and response to common chemotherapy drugs between high-risk and low-risk groups were evaluated. RESULTS: From a total of 8 significantly related modules and 4423 genes, 5 hypoxia-related signature genes were identified to construct a risk model. Further analysis revealed that the overall survival rate (OS) of patients in the low-risk group was significantly higher than the high-risk group. Univariate and multivariate Cox regression analysis showed that the risk scoring signature was an independent factor for prognosis prediction. Analysis of immunocyte infiltration and immunophenotype showed that the immune score and the anticancer immune response in the high-risk were significantly lower than that in the low-risk group. CONCLUSION: The constructed hypoxia-associated prognostic signature demonstrated could be used as a potential risk classifier for PDAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03142-2. BioMed Central 2023-08-22 /pmc/articles/PMC10464224/ /pubmed/37605192 http://dx.doi.org/10.1186/s12957-023-03142-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ren, Min
Feng, Liaoliao
Zong, Rongrong
Sun, Huiru
Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
title Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
title_full Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
title_fullStr Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
title_full_unstemmed Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
title_short Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
title_sort novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464224/
https://www.ncbi.nlm.nih.gov/pubmed/37605192
http://dx.doi.org/10.1186/s12957-023-03142-2
work_keys_str_mv AT renmin novelprognosticgenesignatureforpancreaticductaladenocarcinomabasedonhypoxia
AT fengliaoliao novelprognosticgenesignatureforpancreaticductaladenocarcinomabasedonhypoxia
AT zongrongrong novelprognosticgenesignatureforpancreaticductaladenocarcinomabasedonhypoxia
AT sunhuiru novelprognosticgenesignatureforpancreaticductaladenocarcinomabasedonhypoxia